Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Maravai Lifesciences Holdings Inc (MRVI)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Maravai Lifesciences's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
7.61 -0.13    -1.62%
13:43:34 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 433,967
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 7.52 - 7.76
Maravai Lifesciences 7.61 -0.13 -1.62%

Maravai Lifesciences Holdings Inc Company Profile

 
Get an in-depth profile of Maravai Lifesciences Holdings Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

670

Equity Type

ORD

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Contact Information

Address 10770 Wateridge Circle Suite 200
San Diego, 92121
United States
Phone 858 546 0004
Fax -
Web www.maravai.com

Top Executives

Name Age Since Title
Benjamin James Daverman 42 2020 Non-Independent Director
Anat Ashkenazi 50 2020 Independent Director
Jessica Hopfield 57 2020 Independent Director
Constantine S. Mihas - 2020 Non-Independent Director
Susannah Gray 62 2020 Independent Director
Gregory T. Lucier 58 2020 Independent Director
Sean L. Cunningham - 2020 Non-Independent Director
Murali K. Prahalad 51 2020 Independent Director
Luke Joseph Marker 37 2020 Non-Independent Director
John A. DeFord 61 2023 Director
Carl W. Hull 64 2014 Co-Founder & Executive Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MRVI Comments

Write your thoughts about Maravai Lifesciences Holdings Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Abanoub Mohsen
Abanoub Mohsen Oct 11, 2021 2:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What happens with this stock
Reply
1 0
Report
Abanoub Mohsen
Abanoub Mohsen Oct 11, 2021 2:14PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Only down
Reply
1 0
Report
Юрий Букин
Юрий Букин Mar 03, 2021 10:14AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$MRVI Maintains KeyBanc Overweight USD 39 » USD 46 Maintains Credit Suisse Outperform USD 34 » USD 42
Reply
2 0
Report
Юрий Букин
Юрий Букин Mar 02, 2021 5:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It's a rocket! Revenue of $98.4 million for the fourth quarter and $284.1 million for the full year of 2020, representing 173.5% and 98.5% increases, respectively, over the corresponding periods of 2019; Net income (loss) and Adjusted EBITDA was $78.8 million and $169.2 million, respectively, for the year ended December 31, 2020, compared to $(5.2) million and $62.0 million, respectively, for the prior year. Established 2021 revenue guidance of $580.0 million to $630.0 million, representing growth of 104.2% to 121.8%. https://finance.yahoo.com/news/maravai-lifesciences-reports-fourth-quarter-210500901.html
Reply
0 0
Report
Юрий Букин
Юрий Букин Feb 18, 2021 2:36PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why does no one talk about this company? The company has more than 5 thousand clients, including 20 leading world biopharmaceutical companies (including those testing anti-Covid drugs). For 9M2020, revenues was at $186m vs $143m for the whole 2019 ($124m for 2018); Net profit for 9m2020 was at $64m vs net loss of $5m for the whole 2019 (-$17m for 2018). I suppose it should demonstrate great results for YE2020 on March 2 - demand for its products from pharmaceutical companies should be high. => Bullish
Reply
1 0
Report
Very Long
Very Long Feb 02, 2021 4:57PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Am I the only one who sees EUR/USD page instead of MRVI
Reply
0 0
Report
casey kc
casey kc Feb 02, 2021 4:57PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No. Same here.
Reply
0 0
Report
Very Long
Very Long Feb 02, 2021 4:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why is this page always broken
Reply
0 0
Report
Paco Bv
Pacob Dec 01, 2020 10:52AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Maravai holds a number of patents and offers innovative products and services including CleanCap®, CleanAmp®, GMPLink™, Antibody Affinity Extraction™ (AAE™), EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV™, Sterling™, Glen Pak™, Glen Gel-Pak™, Poly-Pak™, VECTASTAIN® and VECTASHIELD®.
Reply
4 2
Report
Mukhtar Zhangabylov
Mukhtar Zhangabylov Nov 25, 2020 6:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
mthfk...
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email